Product Description: AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2[1].
Applications: Cancer-Kinase/protease
Formula: C25H31N5O4
References: [1]You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31./[2]Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70(1), 288-298./[3]Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27.
CAS Number: 1009298-09-2
Molecular Weight: 465.54
Compound Purity: 99.60
Research Area: Cancer
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: Apoptosis;Autophagy;mTOR
English
Deutsch
